Prime Medicine, INC Form 4 insider transactions

Director Wendy Chung acquired 45,000 stock options in Prime Medicine, Inc. on June 12, 2024.

Director Thomas Cahill acquired 45,000 stock options in Prime Medicine, Inc. on June 12, 2024.

Keith Michael Gottesdiener, President and CEO of Prime Medicine, transferred 250,000 shares of common stock to his spouse for estate planning purposes on June 5, 2024.

Chief Financial Officer of Prime Medicine, Allan Reine, reports the vesting of 100,000 shares underlying a stock option due to the achievement of a performance milestone.

Richard Brudnick, Chief Business Officer of Prime Medicine, reports the vesting of 19,300 shares underlying a stock option due to the achievement of a performance milestone.

Ann L. Lee, Chief Technical Officer of Prime Medicine, Inc., acquired 80,416 shares of common stock through the vesting of a stock option on May 17, 2024, following the achievement of a performance milestone.

Director Jeffrey D Marrazzo acquired 250,000 stock options in Prime Medicine, Inc. on February 29, 2024.

Keith Michael Gottesdiener, a director and officer at Prime Medicine, Inc., acquired 100,000 stock options on February 25, 2024.